Abstract
Ex vivo proliferation and differentiation of Philadelphia chromosome-positive (Ph+) human myeloid cells (Ph+ cells) from chronic myeloid leukemia (CML) proceed via alternation stages of cell proliferation and neutrophil maturation. To regulate them, apoptosis is alternately blocked or induced with the help of neutrophils and expression of bcr/abl, bax, and bcl2. The regulation of apoptosis in main types of Ph+ cells depends on the alternation of (1) Ph+ cell proliferation and (2) neutrophil maturation and may follow two pathways. One consists in alternating blockages and inductions of apoptosis with initial maturation and subsequent proliferation under alternation stages as (2)-(1)-(2) and has not been described as yet. Neutrophil accumulation blocks apoptosis. As neutrophils are depleted, apoptosis is induced again. Its block accelerates proliferation with a new accumulation of neutrophils, which is followed by regular neutrophil death and a new induction of apoptosis. The way optimizes the proliferation efficiency (P/D index) with a regular alternation of maturation and proliferation, allowing the cycle of proliferation and differentiation to be completed. In another way, the alternation starts with proliferation as (1)-(2)-(1) at a lower neutrophil content) and leads to resistant decrease of the maximal apoptosis level by a factor of 3–8 as compared with (2)-(1)-(2) alternation. A stable block of apoptosis is observed in cells with prolonged stages of proliferation and maturation, leading to an accumulation of blasts and myelocytes with elevated bcr/abl expression and expression of bcl2 > bax. A stable block of apoptosis is associated with CML progression and in Ph+ cell lines. Cells follow the first pathway of the apoptotic regulation in chronic-phase CML. Ex vivo cultivation of Ph+ cells from individual CML patients was assumed to provide for a more exact diagnosis of the CML phase and optimizing the treatment.
Similar content being viewed by others
Abbreviations
- CPD:
-
cell proliferation and differentiation
- CML:
-
chronic myeloid leukemia
- Ph+ cells:
-
Philadelphia chromosome-positive cells
- P cells:
-
immature proliferating cells
- D cells:
-
neutrophils, conventionally mature cells
References
Deininger M.W.N., Goldman J.M. 2000. The molecular biology of chronic myeloid leukemia. Blood. 96, 3343–3356.
Melo J.V. 1996. The diversity of the BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 88, 2375–2384.
Jiang X., Eisterer W., Chalandon Y., Porada G., Zanjani E., Eaves A. 2003. New models to investigate mechanisms of disease genesis from primitive BCR-ABL(+) hematopoietic cells. Ann. NY Acad. Sci. 996, 1–9.
Holyoake T.L., Jiang X., Eaves A.C., Eaves C.J. 2002. Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia. Leukemia. 16, 549–558.
Jamieson C.H.M., Ailles L.E., Dylla S.J., Muijtjens M., et al. 2004. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast crisis CML. New Eng. J. Med. 354, 657–667
Buckle A.M., Mottram R., Pierce A., et al. 2000. The effect of Bcr-Abl protein tyrosine kinase on maturation and proliferation of primitive haematopoietic cells. Mol. Med. 6, 892–902.
Primo D., Flores J., Quijano S., Sanchez M.L., et al. 2006. Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia. Br. J. Haematol. 135, 43–51.
Coppo P., Dusanter-Fourt I., Millot G., et al. 2003. Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells. Oncogene. 22, 4102–4110.
Traycoff C.V., Haistead B., Rice S., et al. 1998. Chronic myelogenous leukaemia CD34+ cells exit G0/G1 phases of cell cycle more rapidly than normal marrow CD34+ cells. Br. J. Haetmatol. 102, 759–767.
Abdulkadyrov K.M., Bessemel’tsev S.S., Rukavitsyn O.A. 1998. Khronicheskii mieloleikoz (Chronic Myelogenous Leukaemia). St. Petersburg: Spetsial’naya Literatura.
Vorobyev A.I. 2002. Rukovodstvo po gematologii (A Manual of Hematology). Moscow: Nyudiamed, vol. 1.
Lugovskaya S.A., Pochtar’ M.E., Tupitsin N.N. 2005. Immunotipirovanie v immunodiagnostike gemoblastozov (Immunoty** in Diagnosis of Hemonlastoses). Moscow: Triada.
Cortez D., Kadlec L., Pendergast A.M. 1995. Structural and signaling requeirments for bcr-abl-mediated transformation and inhibition of apoptosis. Mol. Cell Biol. 10, 5531–5541.
Bedi A., Barber J.P., Bedi G.C., El-Deiry W.S., et al. 1995. Bcr-abl-mediated inhibition of apoptosis with delay of G2/M transition after DNA damaged: A mechanism of resistance to multiple anticancer agents. Blood. 86, 1148–1158.
Selleri C., Maciejewski J.P., Pane F., et al. 1998. Fasmediated modulation of bcr/abl in chronic myelogenous leukemia results in differential effects on apoptpsis. Blood. 92, 981–989.
Stoklosa T., Poplawski T., Koptyra M., et al. 2008. Bcr/abl inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res. 68, 2576–2580.
Adams J.M. 2003. Ways of dying: Multiple pathways in apoptosis. Genes Dev. 17, 2481–2495.
Van Delft M.F., Huang D.C.S. 2006. How BCL2 family of proteins interact to regulate apoptosis. Cell Res. 15, 203–213.
Fletcher J. I., Meusburger S., Hawkins C.J., et al. 2008. Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. Proc. Natl. Acad. Sci. U. S. A. 105, 18081–18087.
Amarante-Mendes G.P., Naekyung Kim C., et al. 1998. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood. 91, 1700–1705.
Adams J.M. 2003. Ways of dying: Multiple pathways in apoptosis. Genes Dev. 17, 2481–2495.
Green D.R., Kroemer G. 2004. The patophysiology of mitochondrial cell death. Science. 305, 626–629.
Miyashita T., Kraevsky S., Kraevsky M., et al. 1994. Tumor suppressor p53 is a regulator of BCL2 and Bax gene expression in vitro and in vivo. Oncogene. 9, 1799–1805.
Gesbert F., Griffin J.D. 2000. Bcr/abl activates transcription of the Bcl-X gene through Stat5. Blood. 96, 2269–2276.
Danial N.N. 2007. BCL-2 family proteins: Critical checkpoints of apoptotic cell death. Clin. Cancer Res. 13, 7254–7263.
Niwa H., Burdon T., Chambers I., Smith A. 1998. Selfrenewal of pluripotent embryonic stem cells via activation of STAT3. Genes Dev. 12, 2048–2060.
Grineva N.I., Duchovenskaya E.A., Timofeev A.M., et al. 2012. Gene expression upon proliferation and differentiation of hematopoietic cells with Ph chromosome ex vivo. Acta Naturae. 4, 95–114.
Grineva N.I., Akhlynina T.V., Gerasimova L.P., et al. 2009. Cell regulation of proliferation and differentiation ex vivo for cells containing Ph chromosome in chronic myeloid leukemia. Acta Naturae. 1, 198–120.
Grineva N.I., Akhlynina T.V., Gerasimova L.P., et al. 2010. Differences in proliferation and differentiation of Ph+ cells from individual CML patients in suspension culture: 3. Alternation of proliferation and maturation stages in differentiating Ph+ cells. Ross. Bioterapevt. Zh. 9, 61–76.
Grineva N.I., Akhlynina T.V., Gerasimova L.P., et al. 2009. Differences in proliferation and differentiation of Ph+ cells from different CML patients in culture. Three types of Ph+ cells in CML: Proliferation and differentiation of highly efficient Ph+ cells. Ross. Bioterapevt. Zh. 8, 53–68.
Akhlynina T.V., Grineva N.I., Gerasimova L.P., et al. 2010. Differences in proliferation and differentiation of Ph+ cells from individual CML patients in suspension culture: Ph+ cells with a low efficiency of proliferation and ability to block apoptosis. Ross. Bioterpavt. Zh. 9, 3–12.
Akhlynina T.V., Gerasimova L.P., Sarkisyan G.P., et al. 2007. Kinetics of proliferation, differentiation, and apoptosis regulation gene transcription in human BCR/ABL+ Ph+ cells in culture. Tsitologiya. 49, 889–900.
Rozmarin A.D. 2000. Leukocytes. In: Patofiziologiya krovi (Pathophysiology of Blood). Ed. Shiffman F.D. St. Petersburg: BINOM, pp. 123–148.
Borregaard N., Cowland J.B. 1997. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood. 89, 3503–3521.
Kozinets G.I., Kotel’nikov V.M. 1983. Kinetics of hematopoiesis and its clinical significance. Sov. Med. 4, 3–77.
Abramov M.G. 1985. Gematologicheskii atlas (Hematological Atlas). Moscow: Meditsina.
Grineva N.I., Baryshnikov A.Yu., Gerasimova L.P., et al. 2007. Kinetics of antigen expression during in vitro proliferation and differentiation of Ph+ cells from the peripheral blood of patients with chronic myelocytic leukemia. Ross. Bioterpavt. Zh. 6, 1–32.
Dean P.N. 1980. A simplified method of DNA distribution analysis. Cell Tissue Kinet. 13, 299–302.
Fuchs T.A., Abed U., Goosmann C., Hurwitz R., et al. 2007. Novel cell death program leads to neutrophil extracellular traps. J. Cell Biol. 176, 231–241.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © N.I. Grineva, T.V. Akhlynina, A.M. Timofeev, L.P. Gerasimova, D.A. Schmarov, N.M. Nydenova, T.E. Manakova, T.G. Sarycheva, L.G. Kovaleva, 2013, published in Molekulyarnaya Biologiya, 2013, Vol. 47, No. 4, pp. 642–655.
Rights and permissions
About this article
Cite this article
Grineva, N.I., Akhlynina, T.V., Timofeev, A.M. et al. Apoptosis and neutrophils in the regulation of Ph-positive myeloid cell proliferation and differentiation ex vivo. Mol Biol 47, 559–571 (2013). https://doi.org/10.1134/S0026893313040043
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S0026893313040043